Phocas Financial Corp’s Theravance Biopharma TBPH Stock Holding History

Phocas Financial Corp’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-114	Closed	-$3K	–	283
2018 Q4	$3K	Buy	+114	New	+$3.08K	﹤0.01%	322

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Phocas Financial Corp's TBPH Position: Q1 2019 in Review

Phocas Financial Corp sold out of Theravance Biopharma (TBPH) in Q1 2019, closing a stake of 114 shares — an estimated $3K sold.

Phocas Financial Corp first reported a position in TBPH in Q4 2018 and held it in 1 quarter. The position peaked at $3K in Q4 2018. 104 funds tracked by Wall St. Rank hold TBPH as of Q1 2019.

Phocas Financial Corp reported no remaining Theravance Biopharma position as of Q1 2019 after selling out during the quarter.
Phocas Financial Corp sold 114 Theravance Biopharma shares in Q1 2019, an estimated $3K.
Phocas Financial Corp first reported a position in Theravance Biopharma in Q4 2018 and held it in 1 quarter.
Phocas Financial Corp's Theravance Biopharma position peaked at $3K in Q4 2018.
104 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2019.

Based on Phocas Financial Corp's 13F filing for Q1 2019, filed 13 May 2019.